Question 1

What is PERSEVERE U.S. IDE trial?

Accepted Answer

PERSEVERE U.S. IDE trial is a Other.

Question 2

How often does PERSEVERE U.S. IDE trial appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was PERSEVERE U.S. IDE trial first tracked by Ergen?

Accepted Answer

First tracked on Jun 29, 2026.

Question 4

When was PERSEVERE U.S. IDE trial last mentioned in news?

Accepted Answer

Last active on Jun 29, 2026.

Question 5

What is PERSEVERE U.S. IDE trial's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is PERSEVERE U.S. IDE trial in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving PERSEVERE U.S. IDE trial?

Accepted Answer

Artivion AMDS Prosthesis FDA Approval (Jun 29, 2026, 6 articles).

Question 8

How did the "Artivion AMDS Prosthesis FDA Approval" event impact PERSEVERE U.S. IDE trial?

Accepted Answer

The PERSEVERE U.S. IDE trial provided the clinical data that supported the PMA approval for the AMDS Hybrid Prosthesis, demonstrating its safety and effectiveness in treating acute DeBakey Type I aortic dissections.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.